查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1618302

2024 - 2032 年外分泌胰臟功能不全治疗市场机会、成长动力、产业趋势分析与预测

Exocrine Pancreatic Insufficiency Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 101 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球外分泌胰臟功能不全治疗市场达27亿美元，预计2024年至2032年复合年增长率为5.6%。透过以下方法进行管理：医疗和饮食方法的结合。 EPI 的治疗策略旨在减轻症状、促进营养吸收并改善患者的生活品质。 EPI 诊断技术的重大进步正在改善检测并支持更及时、有效的治疗。最新的研究旨在检测明确的生物标记物，这些标记正在改变胰臟功能评估并促进早期诊断。

粪便弹性蛋白酶-1 已成为一种重要的生物标记物，其低水平表明胰腺功能不全，从而提高了诊断精度并有助于市场扩张。市场按治疗类型分为营养管理和胰酶替代疗法 (PERT)，其中 PERT 细分市场收入领先，到 2023 年将达到 23 亿美元。腹胀和脂肪泻。透过促进脂肪、蛋白质和碳水化合物的适当吸收，PERT 可以预防与 EPI 相关的併发症，包括营养不良、维生素缺乏和意外体重减轻，从而显着改善患者的生活品质。就药物类型而言，市场包括专为 PERT 设计的关键药物，每种药物都提供独特的配方，以增强营养吸收并缓解与 EPI 相关的症状。

利用脂肪酶、蛋白酶和淀粉酶等酶，这些疗法针对效率进行了最佳化，利用肠溶胶囊确保酶在消化发生的小肠中有效释放。这些製剂有多种剂量可供选择，可根据患者的个别需求量身订做治疗方案。 2023 年，北美占据 EPI 治疗市场的主要份额，预计到 2032 年增长将达到 24 亿美元。此外，北美全面的保险覆盖范围和完善的医疗保健系统增强了患者获得专业药物和护理的机会，进一步支持市场扩张并改善患者的治疗结果。市场正在不断发展。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 27亿美元
预测值 44亿美元
复合年增长率 5.6%

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 慢性胰臟炎（CP）和囊性纤维化的盛行率不断增加
      • 人口老化加剧
      • 诊断方面的进步
      • 製药业的技术进步
    • 产业陷阱与挑战
      • 治疗费用高
      • 认识和教育有限
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按处理方式，2021 - 2032 年

  • 主要趋势
  • 营养管理
  • 胰酵素替代疗法（PERT）

第 6 章：市场估计与预测：按药物类型，2021 - 2032 年

  • 主要趋势
  • 克瑞翁
  • 曾佩普
  • 胰脏
  • 维奥卡塞
  • 其他药物种类

第 7 章：市场估计与预测：按症状分类，2021 年 - 2032 年

  • 主要趋势
  • 腹痛
  • 便秘
  • 腹泻
  • 脂肪粪便
  • 减肥
  • 其他症状

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Abbott Laboratories
  • AbbVie
  • Digestive Care
  • Essential Pharma
  • Nestle
  • Nordmark Pharma
  • Sun Pharmaceutical Industries
  • Viatris
  • Vivus
  • Zentiva Pharma UK
简介目录
Product Code: 9379

The Global Exocrine Pancreatic Insufficiency Treatment Market reached USD 2.7 billion in 2023, with a projected growth rate of 5.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency, characterized by a lack of pancreatic enzymes critical for nutrient digestion and absorption, is managed through a combination of medical and dietary approaches. Treatment strategies for EPI aim to reduce symptoms, boost nutrient absorption, and improve the quality of life for those affected by the condition. Significant advancements in diagnostic techniques for EPI are improving detection and supporting more timely, effective treatments. Latest research has aimed at detecting definite biomarkers, which are transforming pancreatic function assessments and facilitating earlier diagnosis.

Fecal elastase-1 has emerged as an essential biomarker, with low levels indicating pancreatic insufficiency, enhancing diagnostic precision and contributing to market expansion. The market is segmented by treatment type into nutritional management and pancreatic enzyme replacement therapy (PERT), with the PERT segment leading in market revenue, reaching USD 2.3 billion in 2023. PERT aids in restoring the body's ability to digest essential nutrients, alleviating common symptoms such as bloating and steatorrhea. By enabling proper absorption of fats, proteins, and carbohydrates, PERT prevents complications associated with EPI, including malnutrition, vitamin deficiencies, and unintended weight loss, significantly improving patients' quality of life. In terms of drug types, the market includes key medications designed for PERT, each offering unique formulations to enhance nutrient absorption and relieve symptoms associated with EPI.

With enzymes like lipase, protease, and amylase, these therapies are optimized for efficiency, utilizing enteric-coated capsules to ensure enzymes are effectively released in the small intestine where digestion occurs. These formulations are available in various dosages, allowing for treatment customization based on individual patient requirements. North America accounted for a major share of the EPI treatment market in 2023, with an anticipated growth reaching USD 2.4 billion by 2032. The region benefits from advanced healthcare infrastructure, extensive research initiatives, and broad access to PERT, driving growth in EPI treatment availability. Additionally, comprehensive insurance coverage and well-established healthcare systems in North America enhance patient access to specialized medications and care, further supporting market expansion and improved patient outcomes.As advancements in diagnostic methods and therapeutic options continue to evolve, the global EPI treatment market is expected to see steady growth.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$2.7 Billion
Forecast Value$4.4 Billion
CAGR5.6%

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis
      • 3.2.1.2 Growing aging population
      • 3.2.1.3 Advancements in diagnosis
      • 3.2.1.4 Technological advancements in pharmaceutical industry
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Limited awareness and education
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Pipeline analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Nutritional management
  • 5.3 Pancreatic enzyme replacement therapy (PERT)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Creon
  • 6.3 Zenpep
  • 6.4 Pancreaze
  • 6.5 Viokace
  • 6.6 Other drug types

Chapter 7 Market Estimates and Forecast, By Symptom, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Abdominal pain
  • 7.3 Constipation
  • 7.4 Diarrhea
  • 7.5 Fatty stools
  • 7.6 Weight loss
  • 7.7 Other symptoms

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 AbbVie
  • 10.3 Digestive Care
  • 10.4 Essential Pharma
  • 10.5 Nestle
  • 10.6 Nordmark Pharma
  • 10.7 Sun Pharmaceutical Industries
  • 10.8 Viatris
  • 10.9 Vivus
  • 10.10 Zentiva Pharma UK